CervoMed (CRVO) Free Cash Flow (2010 - 2026)

CervoMed has reported Free Cash Flow for 17 years, with the latest figure at -$8.0 million in Q1 2026.

• Quarterly Free Cash Flow fell 105.9% year-over-year to -$8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.6 million (down 45.11% YoY) and the FY2025 annual result came in at -$23.4 million, down 41.86% from the prior year.
• Free Cash Flow eased to -$8.0 million in Q1 2026 per CRVO's latest filing, from -$6.6 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $6.9 million in Q3 2022 and troughed at -$8.1 million in Q4 2024.
• A 5-year average of -$3.4 million and a median of -$3.9 million in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow soared 330.67% in 2022, then plunged 266.55% in 2023.
• Over 5 years, Free Cash Flow stood at -$692530.0 in 2022, then slumped by 266.55% to -$2.5 million in 2023, then sank by 217.16% to -$8.1 million in 2024, then gained by 18.32% to -$6.6 million in 2025, then slipped by 21.94% to -$8.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$8.0 million, -$6.6 million, and -$6.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.